Skip to content

Alto Neuroscience ANRO Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
LBR
LB Pharmaceuticals Inc Common StockLBRX

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$887.88M+1,358%
Enterprise value$644.49M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's operating lease right-of-use assets in other assets?
Alto Neuroscience (ANRO) reported operating lease right-of-use assets in other assets of $4.06M in Q1 2026.
How has Alto Neuroscience's operating lease right-of-use assets in other assets changed year-over-year?
Alto Neuroscience's operating lease right-of-use assets in other assets decreased by 16.2% year-over-year, from $4.85M to $4.06M.